ICE in the context of chemotherapy is an acronym for one of the chemotherapy regimens, used in salvage treatment of relapsed or refractory non-Hodgkin's lymphoma and Hodgkin lymphoma.
In case of CD20-positive B cell lymphoid malignancies the ICE regimen is often combined today with rituximab. This regimen is then called ICE-R or R-ICE or RICE.
[R]-ICE regimen consists of:
- (R)ituximab - an anti-CD20 monoclonal antibody, which is able to kill both normal and malignant CD20-bearing B cells;
- (I)fosfamide - an alkylating antineoplastic agent of the oxazafosforine group;
- (C)arboplatin - a platinum based drug, also with an alkylating mechanism;
- (E)toposide - a topoisomerase inhibitor.
Dosing regimen
Cycles are repeated every 14 days for 3 cycles, then high-dose chemotherapy with autologous stem cell transplant follows (if the patient is considered eligible for HDCT and ASCT).
References
ICE (chemotherapy) Wikipedia(Text) CC BY-SA